Evolus, Inc.
EOLS

$784.55 M
Marketcap
$12.39
Share price
Country
$0.41
Change (1 day)
$17.82
Year High
$9.29
Year Low

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

marketcap

Revenue of Evolus, Inc. (EOLS)

Revenue in 2023 (TTM): $202.09 M

According to Evolus, Inc.'s latest financial reports the company's current revenue (TTM) is $202.09 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Evolus, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $202.09 M $140.53 M $-41,810,000 $-61,509,000 $-61,685,000
2022 $148.62 M $92.73 M $-60,723,000 $-74,317,000 $-74,412,000
2021 $99.67 M $56.14 M $-39,058,000 $-46,768,000 $-46,810,000
2020 $56.54 M $38.24 M $-144,752,000 $-162,936,000 $-163,013,000
2019 $34.93 M $26.91 M $-92,103,000 $-105,061,000 $-90,034,000
2018 $ $-9,000 $-46,133,000 $-46,802,000 $-46,867,000
2017 $ $-218,000 $-11,508,000 $-11,731,000 $-4,480,000
2016 $ $-326,000 $-19,640,000 $-19,972,000 $-20,065,000
2015 $ $-416,000 $-30,564,000 $-31,019,000 $-31,112,000